OFFICIAL PUBLICATION OF

by its subsidiary APPco

Keeping your hair on

Chris Brooker 15/04/2019

Leading hair-loss treatment could be set to move to pharmacist-only category Regulators are set to decide on a request to down-schedule a leading hair-loss treatment to the S3 (Pharmacist Only) category. A proposal has been submitted for Finasteride (Propecia, from MSD, and its generic competitors) to be moved to S3, with the sponsor saying pharmacists

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Funding secured for non-8CPA programs

Medschecks and Diabetes MedsCheck are included and funded under the 8CPA. The programs under the 8CPA will be undergoing a…

Anthony Tassone

Eli Lilly clarifies Mounjaro availability

One would think they could have made a commercial decision eith a needle maker to supply requisite number of needles…

Erin Threlfall

Funding secured for non-8CPA programs

This is a big step forward in securing the sustainability and viability of HMRs and RMMRs. Remember there is an…

Debbie Rigby

Funding secured for non-8CPA programs

So well done to the PSA for securing this funding. So important that these very valuable program finally gets looked…

Bente Hart

Keeping your hair on

Previous GP suspended over IGF-1

Next Location rules dispute continues

Shingles: managing a distressing skin condition

Impetigo: cause and treatment

Topical retinoids: versatile skin care ingredients

Ceramides: what are they and why are they important?

MENU

Previous GP suspended over IGF-1

Next Location rules dispute continues

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.